+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thrombosis Drug Market - Global Forecast 2026-2032- Product Image
Thrombosis Drug Market - Global Forecast 2026-2032- Product Image
Sale

Thrombosis Drug Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6084177
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Thrombosis Drug Market is projected to reach USD 34.48 Billion in 2026. It is expected to continue growing at a CAGR of 6.00%, reaching USD 48.84 Billion by 2032.

Thrombosis drugs, including anticoagulants, antiplatelet agents, thrombolytics, and reversal agents, remain central to preventing and treating venous thromboembolism, atrial fibrillation-related stroke, acute coronary syndromes, pulmonary embolism, and device-associated clotting.

The clinical burden is substantial: the International Society on Thrombosis and Haemostasis has reported that thrombosis is associated with roughly one in four deaths worldwide, while the U.S. CDC estimates that venous thromboembolism affects up to 900,000 Americans annually. Demand is therefore anchored by aging populations, higher cardiometabolic disease prevalence, cancer-associated thrombosis, and wider use of invasive cardiovascular procedures.

Transformative Shifts in the Thrombosis Drug Landscape

The thrombosis drug landscape is shifting from broad, laboratory-monitored therapies toward more targeted oral anticoagulants, improved antiplatelet strategies, and safer reversal pathways. Direct oral anticoagulants have changed long-term prevention by reducing the need for routine INR monitoring compared with warfarin, while hospital protocols increasingly emphasize risk stratification, renal function assessment, and bleeding-risk management.

At the same time, innovation is focusing on factor XI and factor XIa inhibition, cancer-associated thrombosis, extended prophylaxis, and post-procedure clot prevention. Competitive advantage is increasingly determined by safety profiles, real-world evidence, payer access, label expansion, and integration into clinical pathways rather than efficacy alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across thrombosis drug discovery, clinical development, and care delivery. AI-enabled target identification, molecular screening, pharmacovigilance signal detection, and trial recruitment analytics can shorten decision cycles and improve the probability of selecting high-value patient populations.

In clinical practice, machine learning models are being tested for venous thromboembolism risk prediction, anticoagulant dosing support, imaging triage, and bleeding-risk stratification. Adoption must remain evidence-led because thrombosis decisions carry high consequences; transparent validation, bias testing, regulatory-grade data governance, and clinician oversight are essential for safe deployment.

Key Regional Insights

Asia-Pacific is becoming a high-growth thrombosis drug region because of aging demographics, expanding hospital capacity, and rising cardiovascular disease in China, India, Japan, South Korea, and Australia. North America remains a premium access environment supported by high diagnosis rates, established anticoagulation guidelines, strong reimbursement for branded therapies, and rapid adoption of reversal agents.

Latin America is improving access through public procurement and private insurance expansion, although affordability and uneven diagnostic infrastructure remain barriers to consistent thrombosis diagnosis and treatment. Europe benefits from guideline-driven prescribing, pharmacovigilance systems, and health technology assessment discipline, while the Middle East is investing in tertiary cardiovascular care and Africa faces the greatest access gap, with opportunities tied to essential anticoagulant availability, laboratory diagnostics, imaging capacity, and clinician training.

Key Group Insights

ASEAN demand is shaped by expanding urban hospital networks, rising diabetes and cardiovascular disease, and procurement-led access to anticoagulants, particularly in large population centers. The GCC is characterized by high cardiometabolic risk, strong specialist infrastructure, and government investment in advanced cardiovascular, emergency, and stroke care services.

The European Union emphasizes evidence-based adoption, pharmacovigilance, and cost-effectiveness, making real-world outcomes essential for reimbursement and formulary decisions. BRICS countries combine large patient pools with price sensitivity, domestic manufacturing priorities, and localization requirements. G7 markets lead in branded innovation, clinical guideline influence, and post-market evidence generation, while NATO members’ healthcare systems reinforce demand for resilient supply chains, secure access to critical medicines, and continuity of care during public health or geopolitical disruption.

Key Country Insights

The United States leads global commercialization due to large treated populations, strong specialist networks, extensive use of direct oral anticoagulants, and established pathways for stroke prevention and venous thromboembolism care, while Canada prioritizes evidence-based reimbursement and provincial formulary access. Mexico and Brazil show rising demand as cardiovascular diagnosis and hospital capacity improve, although out-of-pocket costs, public procurement cycles, and regional disparities influence uptake.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on guideline-led anticoagulation, structured reimbursement review, and payer scrutiny, while Russia remains shaped by domestic supply, pricing dynamics, and formulary controls. China and India offer significant clinical scale but require affordability, physician education, and local access partnerships. Japan, Australia, and South Korea show mature anticoagulation practices supported by aging populations, stroke prevention programs, advanced hospital systems, and strong adoption of evidence-based cardiovascular care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated safety, robust reversal strategies, and label expansion in high-burden indications such as atrial fibrillation, cancer-associated thrombosis, pulmonary embolism, and post-surgical prophylaxis. Real-world evidence should be embedded early to demonstrate reduced hospitalization, lower bleeding-related costs, adherence advantages, and improved care pathway efficiency.

Commercial teams should align market access with local reimbursement logic, invest in clinician education, and support diagnostic pathways for venous thromboembolism and bleeding-risk assessment. Manufacturers should also diversify supply chains for heparins and critical injectables, strengthen pharmacovigilance, and build compliant AI capabilities for trial optimization, patient identification, and post-market safety monitoring.

Research Methodology

This executive summary is based on secondary research and triangulation of public health, regulatory, clinical, and industry sources. Core references include disease-burden data from the CDC, WHO-aligned public health materials, thrombosis society publications, peer-reviewed clinical literature, and regulatory information from agencies such as the FDA and EMA.

The methodology emphasizes validated clinical evidence, guideline relevance, treatment-class assessment, regional access dynamics, and competitive signals across anticoagulants, antiplatelet drugs, thrombolytics, and reversal agents. Insights are interpreted through epidemiology, healthcare infrastructure, reimbursement, safety outcomes, pharmacovigilance requirements, and innovation-readiness lenses.

Conclusion

The thrombosis drug market is supported by persistent clinical need, measurable mortality burden, and expanding use of preventive anticoagulation in high-risk populations. Innovation is moving toward safer mechanisms, more precise patient selection, and integrated treatment pathways that reduce both clotting and bleeding complications.

Future leadership will depend on evidence quality, affordability, regional execution, AI-enabled development, and resilient access to critical therapies. Organizations that combine clinical differentiation with real-world value generation, supply reliability, and responsible digital integration will be best positioned in this essential cardiovascular and hematology market.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Thrombosis Drug Market, by Treatment Type
7.1. Introduction
7.2. Prophylaxis
7.2.1. Medical Prophylaxis
7.2.2. Surgical Prophylaxis
7.3. Therapeutic
7.3.1. Acute Therapy
7.3.2. Long Term Therapy
8. Thrombosis Drug Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intravenous
8.2.2. Subcutaneous
8.3. Oral
8.3.1. Capsule
8.3.2. Tablet
9. Thrombosis Drug Market, by Drug Class
9.1. Introduction
9.2. Antiplatelet Agents
9.3. Direct Oral Anticoagulants
9.3.1. Direct Thrombin Inhibitors
9.3.2. Factor Xa Inhibitors
9.3.2.1. Apixaban
9.3.2.2. Betrixaban
9.3.2.3. Edoxaban
9.3.2.4. Rivaroxaban
9.4. Low Molecular Weight Heparins
9.4.1. Dalteparin
9.4.2. Enoxaparin
9.4.3. Tinzaparin
9.5. Unfractionated Heparins
9.6. Vitamin K Antagonists
10. Thrombosis Drug Market, by Indication
10.1. Introduction
10.2. Atrial Fibrillation
10.3. Deep Vein Thrombosis
10.4. Pulmonary Embolism
11. Thrombosis Drug Market, by End User
11.1. Introduction
11.2. Hospital
11.3. Retail Pharmacy
12. Thrombosis Drug Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Thrombosis Drug Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Thrombosis Drug Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Alkem Laboratories Limited
16.3. Amgen Inc.
16.4. Aspen Pharmacare Holdings Limited
16.5. AstraZeneca PLC
16.6. Baxter International Inc.
16.7. Bayer Aktiengesellschaft
16.8. Boehringer Ingelheim International GmbH
16.9. Bristol-Myers Squibb Company
16.10. Cipla Limited
16.11. Dr. Reddy’s Laboratories Limited
16.12. Eli Lilly and Company
16.13. Fresenius SE & Co. KGaA
16.14. Glenmark Pharmaceuticals Limited
16.15. Hikma Pharmaceuticals PLC
16.16. Johnson & Johnson Services, Inc.
16.17. Lupin Limited
16.18. Merck & Co., Inc
16.19. NATCO Pharma Limited
16.20. Novartis AG
16.21. Pfizer Inc.
16.22. Roche Holding AG
16.23. Sanofi S.A.
16.24. Sun Pharmaceutical Industries Limited
16.25. Teva Pharmaceutical Industries Ltd.
16.26. Torrent Pharmaceuticals Limited
16.27. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL THROMBOSIS DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL THROMBOSIS DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL THROMBOSIS DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL THROMBOSIS DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL THROMBOSIS DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL MEDICAL PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL MEDICAL PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL MEDICAL PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SURGICAL PROPHYLAXIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SURGICAL PROPHYLAXIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SURGICAL PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL THERAPEUTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ACUTE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ACUTE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ACUTE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL LONG TERM THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LONG TERM THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LONG TERM THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIPLATELET AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIPLATELET AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIPLATELET AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL DIRECT ORAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DIRECT ORAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DIRECT ORAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DIRECT THROMBIN INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DIRECT THROMBIN INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DIRECT THROMBIN INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL FACTOR XA INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL FACTOR XA INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL FACTOR XA INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL APIXABAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL APIXABAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL APIXABAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL BETRIXABAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL BETRIXABAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL BETRIXABAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL EDOXABAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL EDOXABAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL EDOXABAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL RIVAROXABAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL RIVAROXABAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RIVAROXABAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL LOW MOLECULAR WEIGHT HEPARINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL LOW MOLECULAR WEIGHT HEPARINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL LOW MOLECULAR WEIGHT HEPARINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL DALTEPARIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL DALTEPARIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL DALTEPARIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ENOXAPARIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ENOXAPARIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ENOXAPARIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TINZAPARIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TINZAPARIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL TINZAPARIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL UNFRACTIONATED HEPARINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL UNFRACTIONATED HEPARINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL UNFRACTIONATED HEPARINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. EUROPE THROMBOSIS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. EUROPE THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 143. EUROPE THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 144. EUROPE THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 145. EUROPE THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. EUROPE THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 147. EUROPE THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 148. EUROPE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 149. EUROPE THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 150. EUROPE THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 151. EUROPE THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 152. EUROPE THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 153. EUROPE THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. AFRICA THROMBOSIS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. AFRICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 169. AFRICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 170. AFRICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 171. AFRICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 172. AFRICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 173. AFRICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 174. AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 175. AFRICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 176. AFRICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 177. AFRICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 178. AFRICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 179. AFRICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. ASEAN THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. ASEAN THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 183. ASEAN THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 184. ASEAN THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 185. ASEAN THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 186. ASEAN THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 187. ASEAN THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 188. ASEAN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 189. ASEAN THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 190. ASEAN THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 191. ASEAN THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 192. ASEAN THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 193. ASEAN THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. GCC THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. GCC THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 196. GCC THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 197. GCC THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 198. GCC THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 199. GCC THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 200. GCC THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 201. GCC THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 202. GCC THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 203. GCC THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 204. GCC THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 205. GCC THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 206. GCC THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. BRICS THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. BRICS THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 222. BRICS THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 223. BRICS THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 224. BRICS THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 225. BRICS THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 226. BRICS THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 227. BRICS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 228. BRICS THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 229. BRICS THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 230. BRICS THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 231. BRICS THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 232. BRICS THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. G7 THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 234. G7 THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 235. G7 THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 236. G7 THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 237. G7 THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. G7 THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 239. G7 THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 240. G7 THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 241. G7 THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 242. G7 THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 243. G7 THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 244. G7 THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 245. G7 THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. NATO THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 247. NATO THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 248. NATO THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 249. NATO THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 250. NATO THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. NATO THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 252. NATO THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 253. NATO THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 254. NATO THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 255. NATO THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 256. NATO THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 257. NATO THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 258. NATO THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 260. UNITED STATES THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 261. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 262. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 263. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 264. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 265. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 266. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 267. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 268. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 269. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 270. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. CANADA THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. CANADA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 275. CANADA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 276. CANADA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 277. CANADA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. CANADA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 279. CANADA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 280. CANADA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 281. CANADA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 282. CANADA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 283. CANADA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 284. CANADA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 285. CANADA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. MEXICO THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. MEXICO THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 288. MEXICO THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 289. MEXICO THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 290. MEXICO THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. MEXICO THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 292. MEXICO THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 293. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 294. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 295. MEXICO THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 296. MEXICO THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 297. MEXICO THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 298. MEXICO THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. BRAZIL THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 301. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 302. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 303. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 304. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 305. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 306. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 316. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 325. GERMANY THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 326. GERMANY THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 327. GERMANY THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 328. GERMANY THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 329. GERMANY THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 330. GERMANY THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 331. GERMANY THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 332. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 333. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 334. GERMANY THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 335. GERMANY THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 336. GERMANY THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 337. GERMANY THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 338. FRANCE THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 339. FRANCE THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 340. FRANCE THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 341. FRANCE THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 342. FRANCE THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 343. FRANCE THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 344. FRANCE THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 345. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 346. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 347. FRANCE THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 348. FRANCE THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 349. FRANCE THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 350. FRANCE THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 351. RUSSIA THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 352. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 353. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 354. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 355. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 356. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 357. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 358. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 359. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2017-2032 (USD MILLION)
TABLE 360. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2017-2032 (USD MILLION)
TABLE 361. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2017-2032 (USD MILLION)
TABLE 362. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 363. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 364. ITALY THROMBOSIS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 365. ITALY THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 366. ITALY THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2017-2032 (USD MILLION)
TABLE 367. ITALY THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2017-2032 (USD MILLION)
TABLE 368. ITALY THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 369. ITALY THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 370. ITALY THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 371. ITALY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2017-

Companies Mentioned

  • Abbott Laboratories
  • Alkem Laboratories Limited
  • Amgen Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer Aktiengesellschaft
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and Company
  • Fresenius SE & Co. KGaA
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 34.48 Billion
Forecasted Market Value ( USD ) by 2032 $ 48.84 Billion
Compound Annual Growth Rate6.0%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Thrombosis Drugs Market Size, Share & Trends Analysis Report by Disease Type (Deep Vein Thrombosis, Pulmonary Embolism), Drug Class, Distribution Channel and Region with Growth Forecasts, 2025-2033 - Product Image

Thrombosis Drugs Market Size, Share & Trends Analysis Report by Disease Type (Deep Vein Thrombosis, Pulmonary Embolism), Drug Class, Distribution Channel and Region with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Thrombosis Drugs - Global Strategic Business Report - Product Image

Thrombosis Drugs - Global Strategic Business Report

  • Report
  • 387 Pages
  • Global
From
Thrombosis Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035 - Product Image

Thrombosis Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035

  • Report
  • 150 Pages
  • Global
From
2025 Global Forecast for Thrombosis Drugs Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Thrombosis Drugs Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Cardiovascular Drugs Market - Global Forecast 2026-2032 - Product Image

Cardiovascular Drugs Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From

About the Thrombosis Drug Market

The Thrombosis Drug market is a subset of the Cardiovascular Drugs market, which focuses on the prevention and treatment of blood clots. Thrombosis drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular events. These drugs work by preventing the formation of blood clots, or by dissolving existing clots. Commonly used thrombosis drugs include anticoagulants, antiplatelet agents, and thrombolytics. Anticoagulants, such as warfarin and heparin, are used to prevent the formation of blood clots. Antiplatelet agents, such as aspirin and clopidogrel, are used to prevent the formation of clots in the arteries. Thrombolytics, such as alteplase and streptokinase, are used to dissolve existing clots. Some companies in the Thrombosis Drug market include Bayer, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.